US equities
|
TSLA
$362.44
▲+0.00%
MU
$931.24
▲+0.00%
SPCX
$148.62
▲+0.00%
SNDK
$1,394.83
▲+0.00%
SKHY
$146.11
▲+0.00%
NVDA
$217.23
▲+0.00%
AMD
$562.23
▲+0.00%
INTC
$95.22
▼-0.16%
TSLA
$362.44
▲+0.00%
MU
$931.24
▲+0.00%
SPCX
$148.62
▲+0.00%
SNDK
$1,394.83
▲+0.00%
SKHY
$146.11
▲+0.00%
NVDA
$217.23
▲+0.00%
AMD
$562.23
▲+0.00%
INTC
$95.22
▼-0.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Pharvaris N.V. - Ordinary Shares
(NQ:
PHVS
)
29.64
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pharvaris N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
October 08, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
October 05, 2026
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
September 08, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones
↗
April 02, 2026
Via
Chartmill
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
↗
September 06, 2026
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Via
MarketBeat
Topics
Artificial Intelligence
Bonds
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 03, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 06, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
↗
July 24, 2026
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 06, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
↗
May 19, 2026
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
↗
May 19, 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
↗
May 11, 2026
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones.
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 11, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 08, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
↗
April 29, 2026
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
↗
April 13, 2026
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 02, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
↗
March 18, 2026
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Via
The Motley Fool
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
↗
March 18, 2026
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Via
The Motley Fool
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
March 02, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
February 10, 2026
Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time
From
Pharvaris N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
